Amgen Inc. $AMGN Position Trimmed by CSM Advisors LLC

CSM Advisors LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 52.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,304 shares of the medical research company’s stock after selling 6,883 shares during the period. CSM Advisors LLC’s holdings in Amgen were worth $1,778,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Brighton Jones LLC grew its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. boosted its position in Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares during the period. Citizens Financial Group Inc. RI boosted its position in Amgen by 63.9% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 15,668 shares of the medical research company’s stock valued at $4,375,000 after purchasing an additional 6,110 shares during the period. Finally, Alberta Investment Management Corp bought a new position in Amgen during the 2nd quarter worth $474,000. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Mizuho raised their target price on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. The Goldman Sachs Group increased their price objective on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Finally, Freedom Capital lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $354.00.

Amgen Trading Up 0.0%

Shares of NASDAQ:AMGN opened at $366.25 on Tuesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a market capitalization of $197.43 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 3.63 and a beta of 0.45. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a 50 day moving average price of $358.64 and a 200 day moving average price of $326.25.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.